Epi-ON corneal crosslinking study for people with Down syndrome
Part of Brain & nervous system, Eyes & vision, Genetic & congenital clinical trials.
This study tests a special light treatment for cornea problems in people with Down syndrome. It aims to strengthen the front of the eye and may help prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 8 or older, any sex or race
- Diagnosed with Down syndrome or similar condition that makes standard exams difficult
- Have keratoconus or another thinning cornea disease
- Able to follow instructions to the best of your ability and attend follow-up visits
- Not pregnant, or if capable of pregnancy, using birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different UV light exposure times (18 minutes vs. 24 minutes) during a corneal crosslinking procedure for people with keratoconus or similar corneal thinning conditions. The goal is to see if the shorter time works as well as the longer one.
This Phase 2 study tests how safe and well a corneal cross-linking device (called PXL-Platinum 330) works for people with corneal ectasia (a thinning/steepening of the cornea). If you qualify, the goal is to help stop or slow further worsening of your cornea shape and improve eye stability.
This trial tests a new combined treatment for keratoconus that includes both a surface laser (phototherapeutic keratectomy) and corneal collagen crosslinking (CXL). It may help strengthen your cornea and improve vision.
This study tests whether treating donor corneal tissue with a special light and vitamin drops (called cross-linking) before a transplant helps improve outcomes for people with keratoconus. If you need a corneal transplant, this could strengthen the donor tissue and potentially reduce the need for future procedures.
This study tests a procedure called corneal crosslinking to slow or stop the progression of keratoconus or corneal ectasia. It might help keep your cornea stable and prevent further vision loss.
This Phase 2 study tests whether a procedure called PXL‑Platinum 330 can safely and effectively strengthen corneas that are thinning (such as keratoconus or related conditions). It aims to see if the treatment can help stabilize or improve the cornea’s shape while keeping side effects low.
Hear when a new Keratoconus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.